GRUPO ESPAÑOL DE CÁNCER DE PULMÓN

PUBLICACIONES

PUBLICACIONES CIENTÍFICAS
2017

  •  Corinne Faivre-Finn, Michael Snee, Linda Ashcroft, Wiebke Appel, Fabrice Barlesi, Adityanarayan Bhatnagar, Andrea Bezjak, Felipe Cardenal, Pierre Fournel, Susan Harden, Cecile Le Pechoux, Rhona McMenemin, Nazia Mohammed, Mary O’Brien, Jason Pantarotto, Veerle Surmont, Jan P Van Meerbeeck, Penella J Woll, Paul Lorigan, Fiona Blackhall, for the CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. www.thelancet.com/oncology Published online June 19, 2017 http://dx.doi.org/10.1016/S1470-2045(17)30318-2
  • Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single arm, phase 2 trial. Lancet Respir Med. 2017 Apr 10. pii: S2213-2600(17)30129-7. doi: 10.1016/S2213 2600(17)30129-7. [Epub ahead of print]
  • Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

2016

  • Romain Corre, Laurent Greillier, Hervé Le Caër, Clarisse Audigier-Valette, Nathalie Baize, Henri Bérard, Lionel Falchero, Isabelle Monnet, Eric Dansin, Alain Vergnenègre, Marie Marcq, Chantal Decroisette, Jean-Bernard Auliac, Suzanna Bota, Régine Lamy, Bartomeu Massuti, Cécile Dujon, Maurice Pérol, Jean-Pierre Daurès, Renaud Descourt, Hervé Léna, Carine Plassot and Christos Chouaïd. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. Published online before print February 16, 2016, doi: 10.1200/JCO.2015.63.5839 JCO February 16, 2016 JCO635839
  • Vergnenegre, B. Massuti, F.de Marinis, E. Carcereny,  E. Felip, P. Do,J.M.Sanchez, L. Paz-Arez, MD,g,i Christos Chouaid, R. Rosell, on behalf of the Spanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French Lung Cancer Group. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. J Thorac Oncol. 2016 Jun;11(6):801-7. doi: 10.1016/j.jtho.2016.02.004. Epub 2016 Feb 18.

2015

  • Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, Itziar de Aguirre, Boris Melloni, Felip Cardenal, Ramon Garcia-Gomez, Bartomeu Massuti, José Miguel Sánchez, Ruth Porta, Santiago Ponce-Aix, Teresa Moran, Enric Carcereny, Enriqueta Felip, Isabel Bover, Amelia Insa, Noemí Reguart, Dolores Isla,  Alain Vergnenegre, Filippo de Marinis, Radj Gervais, Romain Corre, Luis Paz-Ares, Daniela Morales-Espinosa, Santiago Viteri, Ana Drozdowskyj, Núria Jordana-Ariza, Jose Luis Ramirez-Serrano, Miguel Angel Molina-Vila, Rafael Rosell, on behalf of the Spanish Lung Cancer Group. Shorter survival to erlotinib associated with the presence of the EGFR L858R mutation in blood: a prespecified analysis of the EURTAC trial. JAMA Oncol 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.

2014

  • T. Moran, J. Wei, M. Cobo, X. Qian, M. Domine, Z. Zou, I. Bover, L. Wang, M. Provencio, L. Yu, I. Chaib, C. You, B. Massuti, Y. Song, A. Vergnenegre, H. Lu, G. Lopez-Vivanco, W. Hu, G. Robinet, J. Yan, A. Insa, X. Xu, M. Majem, X. Chen, R. de las Peñas, N. Karachaliou, M. A. Sala, Q. Wu, D. Isla, Y. Zhou, N. Baize, F. Zhang, J. Garde, P. Germonpre, S. Rauh, H. ALHusaini, M. Sanchez-Ronco, A. Drozdowskyj, J. J. Sanchez, C. Camps, B. Liu, R. Rosell, on behalf of the Spanish Lung Cancer Group, the French Lung Cancer Group and the Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.  Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies. Annals of Oncology 25: 2147–2155, 2014.. doi:10.1093/annonc/mdu389. Published online 27 August 2014
  • Miguel A Molina-Vila Jordi Bertran-Alamillo, Amaya Gascó, Clara Mayo-de-las-Casas, María Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andrés F Cardona, Alain Vergnenègre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri and Rafael Rosell. Nondisruptive p53 mutations are associated with shorter survival in advanced non-small-cell lung cancer patients. Clin Cancer Res 2014 Sep 1;20(17):4647-59. doi: 10.1158/1078-0432.CCR-13-2391. Epub 2014 Apr 2.
  • Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B, Vergnenegre A, de Marinis F, Molina M.A, Teixido C, Rosell R. “ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation” Translational Lung Cancer Research 2014;3(3):122-130
  • Noemi Reguart, Rafael Rosell, Felipe Cardenal, Andres F. Cardona, Dolores Isla, Ramon Palmero, Teresa Moran, Christian Rolfo, M. Cinta Pallarès, Amelia Insa,Enric Carcereny, Margarita Majem, Javier De Castro, Cristina Queralt,Miguel A. Molina, Miquel Taron.  Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small celllung cancer (NSCLC) patients with epidermal growth factor receptor(EGFR) mutations after erlotinib progression. Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2
  • Translational Lung Cancer Research. Focussed Issue: The 10th Congress of the Spanish Lung Cancer Group. Transl Lung Cancer Res 2014;3(2):64-119

2013

  • Bonano L, Costa C, Majem M, Sánchez JJ, Gímenez-Capitán A, Rodríguez I, Vergnenegre A, Massutí B, Favaretto A, Rugge M, Pallarés C, Tarón M, Rosell R. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy. Oncotarget 10/2013; 4(10):1572-81.
  • B. Massuti, JM Sanchez, F. Hernando-Trancho, N. Karachaliou, R.Rosell. Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?  Transl Lung Cancer Res 2013;2(3):208-221
  • P. Garrido, R. Rosell, A. Arellano, F. Andreu, M. Dómine,A. Perez-Casas, F. Cardenal, MM Arnaiz, Teresa Moránb, R. Morera,D. Isla, J. Valencia,M. Cobo, R. Delgado, R. García-Gómez, F. Calvo, J. Zamorai, A. Ramos, B. Massutí. Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients:Mature results of the Spanish Lung Cancer Group 0008 study. Lung Cancer 81 (2013) 84– 90
  • Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez JJ, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R. BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients with EGFR Mutations. J Thorac Oncol. 2013 Mar;8(3):295-300.

2012

  • Provencio M, Camps C, Cobo M, De las Peñas R, Massuti B, Blanco R, Alberola V, Jimenez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sanchez A, Rosell R. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol. 2012 Dec;70(6):883-90.
  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13 (3):239-246. Epub 2012 Jan 26.
  • Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer. 2012 Jun;76(3):354-61.

2011

  • Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Benlloch S, Viteri S, Gasco A, Mederos N, Carcereny E, Taron M, Rosell R. mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients. J Transl Med. 2011 Sep 27;9:163. doi: 10.1186/1479-5876-9-163.
  • Bover I, Rolfo C, Jantus-Lewintre E, Sirera R, Camps C. Chaib I, Ramirez-Serrano JL. Benlloch s, Molina-Vila MA, Simonetti S, Costa C, Gimenez-Capitan A, Mendez P, Taron M,  Rosell R. Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop. Lung Cancer, 74 (3), 535-543, des.  2011
  • Rosell R, Molina MA, Costa C, Simonetti S,  Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal  F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguar N, Majem M, Viteri  S, Carcereny E, Porta R,  Massuti B, Queralt C, de Aguirre I, Sanchez JM, M, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Taron M. Pre-treatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutation. Clin Cancer Res 17 (5), 1-9 march 2011
  • Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gúrpide A, de Castro J, Polo E, Puig T, Tarón M, Colomer R, Rosell R. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J. 2011 Mar;37(3):624-31. doi: 10.1183/09031936.00195609. Epub 2010 Jul 1.
  • Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients  Lung Cancer. 2011 Apr;72(1):84-91.
  • Viñolas N, Provencio M, Reguart N, Cardenal F,  Alberola V, Sánchez-Torres J.M, Barón FJ, Cobo M, Maestu I,  Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea, Márquez A, Sánchez-Ronco M, Tarón M, Santarpia MC, Rosell R, on behalf of the Spanish Lung Cancer Group. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71 (2011) 191–198

2010 y anteriores

2010

  • Carcereny E, Ramirez JL, Sanchez-Ronco M, Isla D, Cobo M, Moran T, de Aguirre I, Okamoto T, Wei J, Provencio M, Lopez-Vivanco G, Camps C, Domine M, Alberola V, Sanchez JM, Massuti B, Mendez P, Taron M, Rosell R. Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. Lung Cancer, Volume 68, Issue 3 , Pages 491-497, June 2010  PubMed PMID: 19733931.
  • Simonetti S, Molina MA,  Queralt C,  de Aguirre I, Mayo C,  Bertran-Alamillo J,  Sanchez JJ,   Gonzalez-Larriba JL, Jimenez U, Isla D, Moran T, Viteri S, Camps C, Garcia-Campelo R,  Massutí B,  Benlloch S, Ramon y Cajal S,  Taron M, Rosell R. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. Simonetti et al. Journal of Translational Medicine 2010, 8:135.  http://www.translational-medicine.com/content/8/1/135
  • Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Moran T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, TorresA, Camps C, Guijarro R, Isla D, Aguilo R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, Vol 28, No 19 (July 1), 2010: pp. 3138-3145
  • Salazar F, Molina MA, Sanchez Ronco M, Moran T, Ramirez JL; Sanchez J.M, Stahel R., Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo J.M, Sanchez J.J, Taron M, Rosell R. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11.)
  • Provencio M, de Las Peñas R, Camps C, Artal A, Massuti B, Cobo M, Pérez FJ, Sánchez A, Rosell. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential? Lung Cancer 2010, 68 (3): 415-419 PubMed PMID: 19695734.

 

2009

  • Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki F, Wachters FM, Gebbia V, Tsai C-M, Camps C, Schuette  W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli  C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. European Journal of Cancer European Journal of Cancer, 2009  Vol. 46, Issue 4, Pages 735-743
  • Rafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, Manuel Cobo, Teresa Moran, Imane Chaib, Mariano Provencio, Manuel Domine, Maria Angeles Sala, Ulpiano Jimenez, Pilar Diz, Isidoro Barneto, Jose Antonio Macias, Ramon de las Peñas, Silvia Catot, Dolores Isla, Jose Miguel Sanchez,  Rafael Ibeas, Guillermo Lopez-Vivanco, Juana Oramas, Pedro Mendez, Noemi Reguart, Remei Blanco, Miquel Taron. Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. PLoS One. 2009;4(5):e5133. Epub 2009 May 5.
  • Mariano Provencio, Carlos Camps, Vicente Alberola, Bartomeu Massuti, Nuria Viñolas Dolores Isla, Manuel Dómine, Isabel Millán, Manuel Cobo, Rafael Rosell. Lung cancer and treatment in elderly patients: The Achilles Study. Lung Cancer. 2009 Oct;66(1):103-6.
  • Vega Iranzo, Rafael Sirera, A. Carrato, Andrea Cabrera, Eloísa Jantus, Ricardo Guijarro, Elena Sanmartín, Ana Blasco, Mireia Gil, L. Gómez-Aldavarí, J.L.González-Larriba, B. Massuti, A. Velasco, M. Provencio, Rafael Rosell, Carlos Camps. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment of advanced non-small cell lung cancer (GECP 01-04). Clin Lung Cancer 2009 (submitted)
  • Bartolucci R, Wei J, Sánchez JJ, Pérez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto T, Taron M, Rosell R.  XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Clin Lung Cancer. 2009 Jan;10(1):47-52.

 

2008

  • Sirera R, Gil M, Blasco A, Cabrera A, Safont MJ, Iranzo V, Cayuela D, Rosell R, Camps C. Retrospective analysis of the frequency of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. Lung Cancer 2008 Jul;61(1):104-8
  • Safont MJ, Artal-Cortes A, Sirera R, Gómez-Codina J, González-Larriba JL, Barneto I, Carrato A, Isla D, Rosell R, Camps C. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. Lung Cancer. 2009 Jan;63(1):83-7. Epub 2008 Jun 13.
  • Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J, Rosell R. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res. 2008 Aug 1;14(15):4794-9
  • Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, His P, Ding K, Waller D, Le Chevalier T on behalf of the LACE Collaborative Group. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2008 Jul 20;26(21):3552-9
  • Rosell R. Lung Cancer Genes. In response to New treatments hope after lung cancer gene found. published in The Times Online, 3 April 2008.
  • Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, Stahel R, Trigo J, Wei J, Taron M. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small cell lung cancer. Clin Lung Cancer 2008, Vol 9 (Suppl 2): S76-S82
  • Molina MA, Bertran-Alamillo J, Reguart N, Taron M, Castella E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, , Botia M, Pérez-Cano M, Carrasco E, Tomas M, Mate J Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM.A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 2008 Sep 1;14(17):5565-70
  • Gridelli C, Ardizzoni A, Ciardello F, Hanna N, Heymach J, Perrone F, Rosell R, Shephard FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F. Second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2008 Apr;3(4):430-40.
  • Douillard J-Y, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. Impact of post operative radiation therapy (PORT) on survival in completely resected patients with stages I, II or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy in the randomized trial ANITA. Intl J Radiat Oncol Biol Phys 2008 Apr 24. (Epub ahead of print)
  • Garrido P, Massutí B, Cardenal F., Alberola V, Dómine M, Maeztu I, Arellano A, Ramos A, Rosell R (on behalf of the Spanish Lung Cancer Group 0008 investigators). Predictors of long-term survival in lung cancer patients included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clinical Lung Cancer, Invited manuscript
  • L, Moran T and Rosell R. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thor Oncol 2008 , Vol 3, 11: 1224-1235
  • Rosell R , Vergnenegre A, Fournel P,  Massuti B, Camps C , Isla D , Sanchez JM, Moran T, Sirera R and Taron M. Pharmacogenetics in lung cancer for the lay doctor.  Targeted Oncology 2008 , Vol 3 (3): 161-171
  • Taron M, Molina MA, Mendez P, Sirera R, Camps C, Felip E, Massuti B, Carrasco E, Benlloch S, Ramon y Cajal S, Mate JL and Rosell R. The practicalities of pharmacogenomic Analysis- The Spanish Lung Cancer Group Experience. Le Nouveau Cancérologue 2008; 1: 1-3
  • Rosell R, and Garcia-Campelo, R. Farmacogenómica como instrumento de individualización del tratamiento del cáncer. Formación Médica Continuada en Oncología. Jun 2008 Vol 3, Suppl 1: 71-82
  • Perona R, Massuti B, Rosell R. Reflections on the IASLC 12th World Conference on Lung Cancer. Clin Transl Oncol 2008 Feb;10(2):67-9
  • Felip E, Rosell R. Permetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC).The Clin Risk Manag. 2008 Jun;4(3):579-85.

 

2007

  • P. Garrido, JL González-Larriba, A. Insa, M. Provencio, A.Torres, D. Isla, JM. Sánchez, F. Cardenal, M. Domine, J.R Barcelo, V. Tarrazona, A. Varela, R. Aguilo, J. Astudillo, I.Muguruza, A. Artal, F. Hernando-Trancho, B. Massuti, M. Sanchez-Ronco, R. Rosell. Long-Term survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non-Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. Journal of Clinical Oncology. Vol. 25. No 30. : 4736-4742. October 20 2007
  • R.Rosell, M. Taron, JJ. Sánchez, L.Paz Ares. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Medicine. Future Oncol. (2007) 3(3): 277-283
  • M. Cobo, D. Isla, B. Massuti, A. Montes, JM. Sanchez, M.Provencio, N.Viñolas, L. Paz-Ares, Guillermo Lopez-Vivanco, M.A. Muñoz, E. Felip, V. Alberola, C. Camps, M. Domine, J.J. Sanchez, M. Sanchez-Ronco, K. Danenberg, M.Taron, D. Gandara, R. Rosell. Customizing Cisplatin Base on Quatitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer.  Journal of Clinical Oncology.  Vol. 25. No 19: 2747-2754, July 1 2007

 

2006

  • R. Rosell, M. Taron, N. Reguzrt, D. Isla, T. Moran. Epidermical Growth Factor Receptor ctivation: How Exon 19 and 21 Mutations Changed our Understanding of the Pathway. Clin Cancer Res 2006; 12 (24): 7222-7231 (Des. 15, 2006)
  • R. Rosell, M. Taron, M. Galvez, M.C. Pastor, C. Queralt, A. Pradas, M. Botia, M. Pérez, N. Reguart, T. Moran, J.M. Sánchez, M.L. Amador, J.L. Asensio, B. Massutí, L. Paz Ares en nombre del Grupo Español de Cáncer de Pulmón. Determinación de las mutaciones del receptor del factor de crecimiento epidérmico (EGFR) en pacientes con cáncer de pulmón no microcítico tratados únicamente con erlotinib.  Formación Médica continuada Oncología. 2006
  • J-Y. Douillard, R. Rosell, M: de Lena, F. Carpagnano, R. Ramlau, J.L. González-Larriba, T. Grodzki, J. Rodrigues Pereira, A. Le Groumellec, V. Lorusso, C. Clary, A. J. Torres, J. Dahabreh, P.J, Souquet, J. Astudillo, P. Fournel, A. Artal, J. Jassem, L. Koubkova, P. His, M. Riggi, P. Hurteloup. Adjuvant Vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA NSCLC (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.  The Lancet, Vol. 7: 719-727, sept 2006.
  • R. Rosell, M. Cobo, D. Isla, C. Camps, B. Massutí. Pharmacogenomics and gemcitabine. Annals of Oncology, 17, supplement 5): 13-16. may 2006
  • R. Rosell, M. Taron, N. Reguart, F. López-Ríos, L. Paz-Ares, J.L. Ramírez, B. Massutí, M. Cuello, D. Jablons. Pharmacogenomics comes of age in selecting patients for Lung Cancer Treatment. 2006 ASCO Educational Book
  • R. Rosell, M. Cuello, F. Ceccere, MC Santarpia, N. Reguart, E. Felip, M. Taron. Treatment of non-small-cell lung cancer and pharmacogenomics: where ve are and where we are going. Curr Opin Oncol. 2006, 18 (2): 135-143.
  • C. Camps B. Massuti, A. Jiménez, I. Maestu, R. García Gómez, D. Isla, J.L. González, D. Almenar, A. Blasco, R. Rosell, A.Carrato, N. Viñolas, N. Batista, C. García Girón, A. Galán, M. López, R. Blanco, M. Provencio, P. Diz, E.Felip. On behalf of the Spanish Lung Cancer Group. Randomized Phase III Study of Three-Weekly versus Weekly Docetaxel in Pretreated Advanced Non-Small Cell Lung Cancer: A Spanish Lung Cancer Group Trial. Ann Oncol 2006 17(3): 467-472
  • R. de las Peñas, M. Sanchez-Ronco, V. Alberola,  M. Taron, C. Camps, R. Garcia-Carbonero, B. Massuti, C. Queralt, M. Botia, R. Garcia-Gomez, D. Isla, M. Cobo, A. Artal, M.A. Muñoz, I. Bover, D. Almenar, M.Jimenez, J. Terrasa, P. Diz, J.L. Gonzalez-Larriba, R. Barcelo, B. Medina, F. Cardenal, M. Santarpia, F.Cecere, P. Mendez, J.J. Sanchez, R. Rosell, on behalf of the Spanish Lung Cancer Group. Polymorphisms in DNA repair genes modulate survival in cisplatin-plus-Gemcitabine-Treated NSCLC.  Ann Oncol 2006, 17 (4): 669-675

 

2005

  • H. Cortes-Funes, C. Gomez,  R. Rosell, P. Valero, C. Garcia-Giron, A. Velasco, A. Izquierdo, P. Diz, C.Camps, D. Castellanos, V. Alberola, F. Cardenal, J.L. Gonzalez-Larriba, JM Vieitez, I. Maeztu, JJ. Sanchez, C. Queralt, C. Mayo, P. Mendez, T. Moran , M. Taron, on behalf of the Spanish Lung Cancer Group. Epidermal Growth Factor Receptor Activating Mutations in Spanish Gefitinib-Treated Non-Small-Cell Lung Cancer Patients. Annals of Oncology, 16: 1081-1086, 2005
  • Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Maneglod C, Ono M, Queralt C, Jahan T, Sánchez JJ, Sánchez-Ronco  M, Hsue V, Jablons D, Sánchez JM, Moran T. Activating Mutations in the in the Tyrosine Kinase Domain of the Epidermal Growth Factor Reseptor are associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenorcarcinomas. Clinical Cancer Research 2005; 11:5878-5885
  • Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama I, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, Sanchez JJ. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.  Lung Cancer , 2005, 50, 25-33
  • C. Camps, E. Felip, JM. Sánchez, B. Massutí, A. Artal, L. Paz-Ares, A. Carrato, V. Alberola, A. Blasco, J: Baselga, L. Astier, M. Voi, R. Rosell. Phase II trial of the novel taxane BMS-184476 as second-line in NSCLC. Annals of Oncology, 2005 16(4) 597-601
  • R. Rosell, E. Felip, N. Reguart, T. Moran. Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. Future Oncol.(2005) 1(3), 319-322
  • J.L. Ramirez ,R. Rosell, M. Taron, M. Sanchez-Ronco, V. Alberola, R.de las Peñas, J.M. Sanchez, T.Moran, C. Camps, B. Massuti, J.J. Sanchez, F. Salazar, S. Catot, on behalf of the Spanish Lung Cancer Group. 14–3–3s methylation in pre-treatment serum circulating DNA of cisplatin plus gemcitabine-treated non-small-cell lung cancer patients predicts survival. JCO. Vol. 23, nº 30: 9105-9112, desember, 2005
  • R. Rosell, M. Cobo, D. Isla, J.M. Sánchez, M. Taron, G. Altavilla, M Santarpia, T. Moran, O. Etxaniz. Applications of genomics in NSCLC. Lung Cancer, 49 Suppl. (2005) 33-40.

 

2004

  • Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart M, Margeli M, Felip E, Mendez P, Garcia-Campelo R. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004;31:20-27 (Suppl 1)
  • Rosell R. Towards customized trastuzumab in HER-2/neu-overexpresseing non-small-cell lung cancers. J Clin Oncol 2004;22:1-3 (Editorial)
  • Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318-1325
  • Rosell R, Sanchez JM, Taron M, Moran T, Canela M, Ciuraqui B, Felip E, Massuti B, Camps C. Pemetrexed in previously treated non-small-cell lung cancer. Oncology 2004;18(suppl 5):63-71
  • Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J.  Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10 (suppl):4215s-4219s
  • Alberola V, Sarries C, Rosell R, Taron M, de las Peñas R, Camps C, Massuti B, Insa A, Garcia-Gomez R, Isla D, Artal A, Muñoz MA, Cobo M, Bover I, Gonzalez-Larriba JL, Terrasa J, Almenar D, Barcelo R, Diz P, Sanchez-Ronco M, Sanchez JJ. Effect of the methylenetetrahydrofolate C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer patients. Clin Lung Cancer 2004;5:360-365
  • Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A,Medina B, Aartal A, Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.  Annals of Oncology 2004;15:1194-1203
  • Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Sanchez Ronco M, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Gen 2004;13:2443-2449
  • Artal-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, Camps C, Garcia-Giron C, Font A, Maestu I, Cambell J, Rosell R on behalf fo he Spanish Lung Cancer Group. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 2004;6:175-183
  • Rosell R, Felip E, Garcia-Campelo R, Balaña C. The biology of non-small-cell lung cancer: Identifying new targets for rational therapy. Lung Cancer, vol. 46, issue 2, pp 135-148, Nov. 2004
  • Rosell R, Taron M, Sanchez JM, Moran T, Scagliotti G, Isla D, Massuti B, Alberola V, Sanchez JJ. The promise of pharmacogenomics: GEMZAR and ALIMTA. Oncology 2004 Nov; 18 (Suppl 8): 70-6
  • Rosell R, Alberola V, Taron M, Sanchez JM on behalf of the Spanish Lung Cancer Group. New approaches to lung cancer treatment. Current Oncology Reports, Dec 6, Suppl 1: S 16-17

 

2003

  • Camps C, Sàrries C, Roig B, Sánchez JJ, Queralt C, Sancho, E, Martínez N, Taron M, Rosell R. Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin-Treated Locally Advanced NSCLC patients. Clinical Lung Cancer, vol 4 nº 4, 237-241, 2003
  • Alberola V, Camps C,  Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sánchez JJ, de las Peñas R, Felip E, López-Vivanco G. Cisplatin/Gemcitabine versus a Cisplatine-Bases Triplet versys Non-Platinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A spanish Lung Cancer Group Phase III Randomized Trial. Journal of clinical Oncology, Vol 21 Nº 17 (september 1), 2003: pp 3207-3213
  • Rosell R, Taron M, Alberola V, Massutí B, Felip E, Spanish Lung Cancer Group. Genetic testing for chemotherapy in non-small-cell lung cancer. Lung Cancer vol. 41 ; 97-102 (2003)
  • Ramirez JL, Sàrries C, López de Castro P, Roig B, Queralt C, Escuin D, de Aguirre I, Sánchez JM, Manzano JL, Margelí M, Sánchez JJ, Astudillo J, Taron M, Rosell R. Methylation Patterns and K-ras Mutations in Tumor and Paired Serum of Resected NSCLC patients. Cancer Letters, vol. 193, Issue 2. 207-216 (April 2003)
  • Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide Excision Repair Pathways involved in Cisplatin Resistance in NSCLC. Cancer Control, Jul/August 2003, Vol 10 Nº 4: 297-305
  • Felip E, Rosell R, Dómine M, Santomé L, Garrido P, Font A, Carrato A, Terrasa J, Vadell C, Mañé JM, Baselga J, on the behalf of the SLCG. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage SCLC: a SLCG  phase II study. Annals of Oncology Vol 14 Nº 10: 1549-1554, october 2003
  • Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G, Taron M, Alberola M, Provencio M; Camps C, De Marinis F, Sánchez JJ, de las Peñas R. Targeted Therapy in combination with Gemcitabine in Non-Small Cell Lung Cancer. Seminars in Oncology, Vol 30 nº 4 Suppl 10 (August), 2003 pp 19-25
  • Cardenal F, Dómine M, Massutí B, CArrato A, Felip E, Garrido P, Juan O, Artal A, Barneto I, López-Vivanco G, Balcells M, Rosell R. Three-week schedule of ironotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer, vol. 39/2, 201-207, 2003

 

2002

Rosell R, Taron M, Sàrries C, Queralt C, Roig B. B-tubulin mutational analysis: tantalizing findings. Lung Cancer, Letter to the Editor Vol 38 Issue 1 (october, 2002); 99-100

  • Rosell R, Lord Reginald VN, Taron M, Reguart N. DNA repair and cisplatin resistance in NSCLC. Lung Cancer, vol 38 issue 3: 217-227 (Des. 02)
  • Rosell R, on the behalf of the Spanish Lung Cancer Group, Fossella F, Milas F. Molecular markets and targeted therapy with novel agents: prospects in the treatment of NSCLC. Lung Cancer, vol 38,  supl. 4, 43-49 (Des. 02)
  • Sàrries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, Rosell R. Pharmacogenomic strategies for developing customized chemotherapy in NSCLC. Pharmacogenomics (2002) 3 (6), 763-780
  • Sánchez, JM, Balañá C, Font A, Sánchez JJ, Manzano JL, Guillot M, Margelí M, Richardet M, Rosell R. Phase II non-randomized study of three diferent sequences of docetaxel and vinorelbine in patients with advanced NSCLC. Lung Cancer , vol 38, issue 3, 309-315 (Des.02)
  • Reginald V. N. Lord, Jan Brabender, David Gandara, Vicente Alberola, Carlos Camps, Manuel Domine, Felip Cardenal, José M. Sánchez, Paul H. Gumerlock, Miquel Tarón, José J. Sánchez, Kathleen D. Danenberg, Peter V. Danenberg and Rafael Rosell. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer. Clinical Cancer Research Vol. 8, 2286-2291, July 2002.
  • Monzo M, Taron M, Rosell M. Genetic Analysis of the B-tubulin Gene, TUBB in NSCLC. Journal of the National Cancer Institute, Vol. 94 nº 10, 774-777, May 15, 2002
  • Rosell R, Garzemeier U, Betticher DC, Kepppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. Phase III randomised trial comparing paclitaxel/carboplatin with paclitasel/cisplatin in patients with advanced NSCLC: a cooperative multinational trial. Annals of Oncology 13:1539-1549, 2002

Switch The Language

Award winning creative agency

We are building for tomorrow because tomorrow is the future and we want to make a contribution to the wonderful digital age that is awaiting us.